Systemic sclerosis (SSc) is a complex disease involving various factors like immune system dysfunction and tissue scarring in the skin and vital organs. It's difficult to predict and treat because it varies greatly among patients.
This study of Yehya Mohammed focused on understanding how the disease starts and progresses, especially its impact on the lungs. Monocytes and macrophages, types of immune cells, play a key role in both the early and late stages of Systemic sclerosis by triggering inflammation and scarring. The study suggested potential treatments targeting these cells. Another focus was on Raynaud's phenomenon, an early sign of Systemic sclerosis, which may trigger the disease through oxidative stress.
We found a protein called HMGB1 which may be involved in early pathogenesis, opening up new treatment possibilities. Serious complications involving the lungs like pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) can be fatal. The study identified biomarkers, like CXCL10, which could help predict lung issues early. Additionally, we discovered genes associated with the progression of lung fibrosis, suggesting new ways to intervene. Overall, the study suggests targeting inflammation early on could be more effective in managing Systemic sclerosis and its lung complications. However, challenges remain in diagnosing and treating the disease promptly.
